{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-207466","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2024-08-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.780717+00:00","generated_at":"2026-05-31T07:27:13.019391+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Invivyd's pemivibart shows 84% relative risk reduction in symptomatic COVID-19 in Phase 3 exploratory analysis","bullets":["84% relative risk reduction vs placebo (1.9% vs 11.9% symptomatic COVID-19 rate, p=0.000061) over 180 days in immunocompetent cohort.","Immunocompromised cohort: 3% symptomatic COVID-19 rate; no COVID-19 hospitalizations or deaths over 180 days.","Safety: anaphylaxis in 0.6% of immunocompromised cohort (2 life-threatening); infusion reactions generally mild-moderate.","FDA updated PEMGARDA Fact Sheet for Healthcare Providers to include 180-day exploratory efficacy data.","Data collected during XBB/JN.1 variant waves; company to host conference call at 8:30AM EDT today."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-207466","json":"https://secwatch.observer/filing/0001193125-24-207466.json","markdown":"https://secwatch.observer/filing/0001193125-24-207466.md","text":"https://secwatch.observer/filing/0001193125-24-207466.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000119312524207466/0001193125-24-207466-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000119312524207466/d890200d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:27:13.019391+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}